Excipient Compatibility Studies
Excipients are pharmacologically inert substances included in a formulation to impart bulk, aid manufacture, control release, or enhance stability, yet...
Excipients are pharmacologically inert substances included in a formulation to impart bulk, aid manufacture, control release, or enhance stability, yet despite their pharmacological inertness, excipients are capable of chemical or physical interaction with the active drug substance, and undetected incompatibilities represent one of the most common causes of stability failure in pharmaceutical products. Excipient compatibility studies are therefore conducted systematically during preformulation to identify and eliminate problematic excipient combinations before they are incorporated into a formal formulation.
The standard methodology involves preparing binary mixtures of the drug with each candidate excipient, typically at both a one-to-one and a one-to-five drug-to-excipient ratio, in order to accentuate any interaction that might otherwise be masked by a large excipient excess in the final formulation. These binary mixtures are stored under accelerated stress conditions, conventionally forty degrees Celsius and seventy-five per cent relative humidity, for a period of approximately four weeks, after which they are analysed by a combination of visual inspection, Differential Scanning Calorimetry, and high-performance liquid chromatography.
Incompatibilities are broadly classified into physical and chemical categories. Physical incompatibility manifests as observable changes such as colour alteration, liquefaction, or gas evolution, and is detected through straightforward visual inspection. Chemical incompatibility is more insidious, frequently undetectable by eye, and is revealed through the appearance of new peaks on high-performance liquid chromatography corresponding to degradation products, or through an unacceptable loss of drug assay, conventionally a decline exceeding five per cent. Differential Scanning Calorimetry provides a complementary line of evidence, since a shift or disappearance of the drug's characteristic melting endotherm in the presence of an excipient, or the appearance of a new eutectic transition, is strongly suggestive of a molecular-level interaction.
Certain excipient-drug incompatibilities recur across the pharmaceutical literature and are well documented as cautionary examples: magnesium stearate, a near-ubiquitous tablet lubricant, is known to catalyse the hydrolytic degradation of aspirin; lactose, an extremely common diluent, undergoes the Maillard reaction with primary and secondary amine-containing drugs, producing discoloured degradation products; and microcrystalline cellulose, despite its general inertness, can interact adversely with highly hygroscopic active substances by locally concentrating absorbed moisture. Awareness of such precedents allows the preformulation scientist to anticipate and pre-emptively screen for analogous risks in structurally related molecules.